Actively Recruiting
Phase 1 Study of SynKIR-310, a Modified T Cell Therapy, for Adults With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Led by Verismo Therapeutics · Updated on 2026-04-14
36
Participants Needed
5
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, feasibility, and initial effects of a single intravenous dose of SynKIR-310 in adults with relapsed or refractory B-cell Non-Hodgkin Lymphoma B-NHL. This first-in-human Phase 1 trial includes up to 36 participants with various B-NHL subtypes to better understand how this treatment works in this patient group. SynKIR-310 is an autologous T cell therapy modified with CD19 KIR-CAR, aiming to explore its potential in cases where previous treatments have failed or been declined. Participants will receive one intravenous infusion of SynKIR-310. The study involves up to four groups with increasing doses to find the best dose for further study, called the Recommended Phase 2 Dose RP2D. After determining the RP2D, additional participants will receive this dose to gather more information on safety, feasibility, and initial response to treatment. Throughout the study, participants will be monitored for up to 24 months to assess safety and treatment effects. Researchers will evaluate response rates, duration of response, and how the body processes SynKIR-310. Regular assessments will include disease measurements, physical exams, and laboratory tests. This close monitoring helps understand how well the treatment is tolerated and its impact on lymphoma over time.
CONDITIONS
Brief Title
SynKIR-310 for Relapsed/Refractory B-NHL
Research Team
P
Physician Connect
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here